2nd Industry-Government Cancer Genomic Medical Association front-line exchange(December 6, 2019) was held by 22CEMIT.
The technology developed by Natera Inc "To judge the possibility of cancer recurrence at 90% accuracy" has been invterviewd by TV Asahi Corporation.
This technology has already been decided to be covered by insurance in USA, and expectations are growing for it to be introduced in Japan.
Click here for details:
https://news.tv-asahi.co.jp/news_economy/articles/000171051.html
English 
Japanese